<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038037</url>
  </required_header>
  <id_info>
    <org_study_id>2009-015068-32</org_study_id>
    <nct_id>NCT01038037</nct_id>
  </id_info>
  <brief_title>First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer</brief_title>
  <acronym>Lung-TRIO</acronym>
  <official_title>A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of panitumumab to standard&#xD;
      chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the&#xD;
      treatment outcome. Patients are selected based on triple mutational status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced NSCLC holds a very poor prognosis with a moderate response rate to standard&#xD;
      chemotherapy. The standard first-line treatment for advanced NSCLC is platinum based&#xD;
      combination chemotherapy. The response rates are less than 30% and a substantial amount of&#xD;
      patients will experience unnecessary toxicity in terms of e.g. nausea, vomiting, neuropathies&#xD;
      or a considerable risk of renal toxicity. The median progression free survival is 3-4 months&#xD;
      and consequently, the median overall survival is less than one year (Hotta et al 2007).&#xD;
      Addition of new biological agents to standard chemotherapy regimens may improve the outcome&#xD;
      for these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1. Very low enrollment rate.&#xD;
&#xD;
      2. Recent studies question the effect of adding panitumumab in this category of patients.&#xD;
&#xD;
      3. Too high toxicity rate&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>i.v. day 1: AUC 5 x (GFR + 25) mg q3w</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab</intervention_name>
    <description>i.v. day 1: 9 mg/kg q3w</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic (stage IV) NSCLC&#xD;
&#xD;
          -  Measurable disease according to RECIST v.1.0 2009&#xD;
&#xD;
          -  KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue.&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  PS &lt; 2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Haematology:&#xD;
&#xD;
          -  Neutrophil count ≥1.5x10^9/L&#xD;
&#xD;
          -  Platelet count ≥100x10^9/L&#xD;
&#xD;
          -  Leucocyte count &gt; 3,000/mm&#xD;
&#xD;
        Hepatic function:&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times the upper normal limit (UNL)&#xD;
&#xD;
          -  Serum transaminases ≤ 2.5xUNL in absence of liver metastases, or ≤ 5xUNL in presence&#xD;
             of liver metastases&#xD;
&#xD;
        Renal Function:&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min and serum creatinine ≤ 1.5xUNL&#xD;
&#xD;
        Metabolic function:&#xD;
&#xD;
          -  Magnesium ≥ lower limit of normal.&#xD;
&#xD;
          -  Calcium ≥ lower limit of normal.&#xD;
&#xD;
        Consent to translational research studies&#xD;
&#xD;
        Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) ≤ 1 year before enrollment/randomization, active severe infections or&#xD;
             other concurrent disease.&#xD;
&#xD;
          -  Known CNS metastasis (pretreatment routine assessment not required)&#xD;
&#xD;
          -  Prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Indication for radiation therapy or prior radiotherapy within 30 days before treatment&#xD;
             start.&#xD;
&#xD;
          -  Other malignant diseases within 5 years prior to inclusion in the study, except basal&#xD;
             cell squamous carcinoma of the skin and cervical carcinoma-in-situ.&#xD;
&#xD;
          -  Other experimental therapy within 30 days prior to treatment initiation.&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          -  Patients pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          -  Patients (male or female) not willing to use highly effective methods of contraception&#xD;
             (per institutional standard) during treatment and for 6 months (male or female) after&#xD;
             the end of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Triple mutational status</keyword>
  <keyword>KRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>PI3K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

